OrganoClick (ORGC) Q1 2026 earnings summary

Executive summary

• Achieved positive operating profit (EBIT SEK 320k) in Q1 2026, reversing prior negative trends despite a 22.7% year-over-year sales decline to SEK 27.4 million.

• Gross margin improved to 30.5% from 25.2% due to a higher share of consumer products and cost reductions.

• Cash flow from operating activities improved sharply to SEK -435k from SEK -10.5 million year-over-year.

• Savings program of SEK 20 million implemented, with nearly full effect in Q1 2026.

Financial highlights

• Net sales: SEK 27,367k (down from SEK 35,397k, -22.7% year-over-year).

• EBIT: SEK 320k (up from SEK -2,100k).

• Gross profit: SEK 8,340k (vs. SEK 8,937k), gross margin 30.5% (up from 25.2%).

• Earnings per share: SEK -0.02 (improved from SEK -0.04).

• Cash and cash equivalents: SEK 3,052k (up from SEK 401k).

• Net debt/equity ratio: 508.4% (up from 311.3%).

Outlook and guidance

• Announced loss of a major industrial customer from July 2026, expected to reduce annual sales by ~25%.

• Additional SEK 5 million cost savings program initiated to offset lost sales.

• Focus shifting further toward higher-margin consumer products for future growth.